DUBLIN–(BUSINESS WIRE)–The “Drug Discovery Outsourcing Market Report 2023-2033” report has been added to ResearchAndMarkets.com’s offering.
Drug Discovery Outsourcing Market value will surpass US$1.644 Billion in 2023
The report predicts strong revenue growth through to 2033. The work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Faced with declining innovation and increasing financial pressure to reduce R&D expenditures across the board, pharmaceutical companies have realised that the top-down, blockbuster model of drug discovery is no longer viable. Therefore, there is currently a trend in the pharma market of shifting towards a more distributive model for R&D. In order to ensure future revenue growth, the pharmaceutical industry needs to refocus their investment on early drug discovery.
Public-private partnerships where companies form alliances with academic research laboratories have been suggested as the way forward. The advantage of this approach is that the results of drug discovery research would be made publicly available for everyone to see.
The advantage of this approach is that the results of drug discovery research would be publicly available for everyone to see. This would leverage the expertise of global academia with the potential to arrive at therapies more quickly.
What Questions Should You Ask before Buying a Market Research Report?
- How is the drug discovery outsourcing market evolving?
- What is driving and restraining the drug discovery outsourcing market?
- How will each drug discovery outsourcing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
- How will the market shares for each drug discovery outsourcing submarket develop from 2023 to 2033?
- What will be the main driver for the overall market from 2023 to 2033?
- Will leading drug discovery outsourcing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
- Who are the leading players and what are their prospects over the forecast period?
- What are the drug discovery outsourcing projects for these leading companies?
- How will the industry evolve during the period between 2023 and 2033?
- What are the implications of drug discovery outsourcing projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the drug discovery outsourcing market?
- Where is the drug discovery outsourcing market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
Market Dynamics
Market Driving Factors
- Reduced Pharmaceutical and Biotech R&D Budgets
- Emerging Markets are a Popular Destination for CROs
- Improving Conditions in the Industry will Drive Healthy Growth
- Cost Reduction: A Central Driver for Outsourcing
- Accelerating the Discovery of Drug Candidates
Market Restraining Factors
- Limited IP Protection
- Threat of Private Public Alliances
Market Opportunities
- Strategic Partnerships to Offer Lucrative Growth Prospects
- Investment in Artificial Intelligence to Offer Fresh Revenue Pockets
- Available Scope for the Expansion of CROs
- Targeted Therapies: Advances in Biologics and Orphan Drugs
COVID-19 Impact Analysis
R&D Outsourcing Business Model (Fee-for-Service)
Collaborations Between CRO and Pharmaceutical Industry
Porter’s Five Forces Analysis
Leading companies and the potential for market growth
- Aragen Life Sciences Pvt. Ltd. (GVK Biosciences)
- Charles River Laboratories
- Curia Global, Inc.
- Dalton Pharma
- Domainex
- Eurofins
- Evotec AG
- Genscript
- Jubilant Biosys Ltd.
- Laboratory Corporation of America Holdings
- Pharmaron
- QIAGEN N.V.
- Selvita
- Sundia Meditech Co Ltd.
- Sygnature Discovery
- Syngene International
- Thermo Fisher Scientific Inc.
- WuXi AppTec
Segments Covered in the Report
Service Type
- Chemistry Services
- Biology Services
Workflow
- Target Identification & Screening
- Target Validation & Functional Informatics
- Lead Identification & Candidate Optimization
- Preclinical Development
- Other Associated Workflow
Therapeutic Area
- Oncology
- Infectious Disease
- Central Nervous System
- Immunology
- Cardiovascular Disease
- Metabolic Disease
- Respiratory Disease
- Others
Molecule Type
- Large Molecules
- Small Molecules
End-users
- Pharmaceutical & Biotechnology Companies
- Academic Institutes
- Others
Companies Mentioned
- Aragen Life Sciences Pvt. Ltd. (GVK Biosciences)
- Charles River Laboratories
- Curia Global, Inc.
- Dalton Pharma
- Domainex
- Eurofins
- Evotec AG
- Genscript
- Jubilant Biosys Ltd.
- Laboratory Corporation of America Holdings
- Pharmaron
- QIAGEN N.V.
- Selvita
- Sundia Meditech Co Ltd.
- Sygnature Discovery
- Syngene International
- Thermo Fisher Scientific Inc.
- WuXi AppTec
- Absorption Systems
- Allergan Biologics Limited
- Amphista Therapeutics Ltd .
- Amphista Therapeutics Ltd.
- Arsenal Biosciences, Inc.
- ASC Therapeutics
- ATEM Structural Discovery (ATEM)
- Avectas
- Beijing Apollo Venus Biomedical Technology Limited
- Berkeley Lights, Inc.
- BLIRT S.A.
- Blueprint Medicines Corporation
- Bristol Myers Squibb
- Celltrio
- Chinook Therapeutics, Inc.
- Cognate BioServices
- ConcertAI, LLC
- Cypre, Inc.
- Cyprotex
- Daewoong Pharma
- Discovery Life Sciences
- Eli Lilly and Company
- Epigeneron Inc.
- Explora BioLabs Holdings, Inc.
- Fidelta
- Galapagos NV
- GlaxoSmithKline (GSK)
- GVK BIO
- HealthVerity, Inc.
- IAMA Therapeutics
- Iktos
- IMIDomics, Inc.
- Integrity Bio
- Johnson & Johnson
- Kazia
- KWS BioTest
- LakePharma
- Legend Biotech Corporation
- Merck
- Myriad Genetics’
- Nanoscope Therapeutics, Inc.
- NeoVac
- NovAliX
- Novartis
- Novo Nordisk
- Ovia Health
- OXGENE
- OxVax
- Peak Proteins Ltd.
- PeproTech, Inc.
- Pfizer
- Pharmaron Beijing Co., Limited
- Pharos Therapeutics
- Prisma Health
- Purespring Therapeutics
- ReachBio Research Labs
- Related Sciences
- Retrogenix Limited
- Rigenerand Srl
- Roche
- Rznomics Inc.
- SAMDI Tech, Inc.
- Sandoz AG
- SB Drug Discovery
- SB Drug Discovery
- Secarna Pharmaceuticals GmbH & Co. KG
- Sernova Corp
- Sintalica Bioscience Corp.
- Skyhawk Therapeutics
- Stirling Square Capital Partners
- Sysmex Corporation
- Taros Chemicals
- Toxikon Corporation
- Tubulis GmbH
- Valo Health, Inc.
- Vigene Biosciences, Inc.
- Xcell Biosciences, Inc.
- Ziphius Vaccines
- Bill & Melinda Gates Foundation
- Biomedical Advanced Research and Development Authority (BARDA)
- Bioprocessing Technology Institute (BTI)
- Cure AP-4
- Department of Health and Human Services (HHS)
- German Federal Ministry of Education and Research (BMBF)
- Helmholtz Center for Infection Research (HZI)
- Manchester Cancer Research Centre (MCRC)
- MD Anderson Cancer Center Foundation
- National Center for Research and Development (NCRD)
- Personalised Medicine (PerMed)
- Pharmaceutical Research and Manufacturers Association (PhRMA)
- Tigerlily Foundation
- University Hospital Erlangen
- U.S. Department of Defence (DOD)
- University Medical Center Hamburg-Eppendorf (UKE)
- University of Bristol (UoB)
- University of Sydney
- Yale University
For more information about this report visit https://www.researchandmarkets.com/r/ixp017
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900